← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,042	+10	+0.5%	$157B
2	2 Danaher DHR $158B	1,776	-17	-0.9%	$127B
3	3 Novartis NVS $279B	1,136	-41	-3%	$18.7B
4	4 Illumina ILMN $41B	1,046	+60	+6%	$50.8B
5	5 Regeneron Pharmaceuticals REGN $80.1B	924	+20	+2%	$42.3B
6	6 Agilent Technologies A $49.1B	873	+31	+4%	$33.2B
7	7 Revvity RVTY $17B	583	-15	-3%	$13.4B
8	8 Charles River Laboratories CRL $14.4B	561	+22	+4%	$13.7B
9	9 ARK Genomic Revolution ETF ARKG $2.05B	508	+93	+22%	$2.24B
10	10 DELISTED CATALENT, INC. CTLT	500	-7	-1%	$17.6B
11	11 CRISPR Therapeutics CRSP $4.86B	444	+32	+8%	$5.2B
12	12 Guardant Health GH $21.9B	419	0	0%	$13.9B
13	13 Alnylam Pharmaceuticals ALNY $30B	391	+15	+4%	$15.4B
14	NVTA 14 DELISTED Invitae Corporation NVTA	373	+22	+6%	$6.97B
15	15 Sarepta Therapeutics SRPT $1.78B	367	-88	-19%	$4.97B
16	16 Ionis Pharmaceuticals IONS $7.1B	365	-18	-5%	$5.55B
17	17 Azenta AZTA $1.63B	337	+21	+7%	$5.66B
18	18 10x Genomics TXG $9.52B	324	+19	+6%	$12.8B
19	19 Editas Medicine EDIT $349M	314	+2	+0.6%	$2.23B
20	20 Arrowhead Research ARWR $8.25B	289	-20	-6%	$4.55B
21	21 Qiagen QGEN $9.41B	275	+6	+2%	$5.97B
22	22 Pacific Biosciences PACB $619M	262	+52	+25%	$5.47B
23	23 Intellia Therapeutics NTLA $1.6B	261	+20	+8%	$5.07B
24	24 Fate Therapeutics FATE $232M	260	+12	+5%	$7.73B
25	25 Fulgent Genetics FLGT $578M	256	+60	+31%	$973M